Main > ONCOLOGY (**) > Lung>NSCLC>EGFR Exon20 Insertion+> > JP. T. TKI Oral



JP. T. TKI Oral's subsections
(*) USA Approval Date: 2021. 09.15
>MET
Companion DIAG.:
Company
EGFR: epidermal growth factor recep
Generic Name: mobocertinib
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 2
Patent>UpDate: 2021. 09.14
PR Web-Site
TKI: tyrosine kinase inhibitor

JP. T. TKI Oral's products
This section has no products